Evaluation of Operational Models of Agonism and Allostereism at Receptors with Multiple Orthosteric Binding Sites[§]

Karen J. Gregory, Jesús Giraldo, Jiayin Diao, Arthur Christopoulos, and Katie Leach

Drug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Melbourne, Australia (K.J.G., J.D., A.C., K.L.); Laboratory of Molecular Neuropharmacology and Bioinformatics, Institut de Neurociències and Unitat de Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain (J.G.); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, Bellaterra, Spain (J.G.); and Unitat de Neurociència Traslacional, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí and Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain (J.G.)

Received August 12, 2019; accepted November 4, 2019

ABSTRACT

Current operational models of agonism and allostereism quantify ligand actions at receptors where agonist concentration-response relationships are nonhyperbolic by introduction of a transducer slope that relates receptor occupancy to response. However, for some receptors nonhyperbolic concentration-response relationships arise from multiple endogenous agonist molecules binding to a receptor in a cooperative manner. Thus, we developed operational models of agonism in systems with cooperative agonist binding and evaluated the models by simulating data describing agonist effects. The models were validated by analyzing experimental data demonstrating the effects of agonists and allosteric modulators at receptors where agonist binding follows hyperbolic (M_4 muscarinic acetylcholine receptors) or nonhyperbolic relationships (metabotropic glutamate receptor 5 and calcium-sensing receptor). For hyperbolic agonist concentration-response relationships, no differences in estimates of ligand affinity, efficacy, or cooperativity were observed when the slope was assigned to either a transducer slope or agonist binding slope. In contrast, for receptors with nonhyperbolic agonist concentration-response relationships,

estimates of ligand affinity, efficacy, or cooperativity varied depending on the assignment of the slope. The extent of this variation depended on the magnitude of the slope value and agonist efficacy, and for allosteric modulators on the magnitude of cooperativity. The modified operational models described herein are well suited to analyzing agonist and modulator interactions at receptors that bind multiple orthosteric agonists in a cooperative manner. Accounting for cooperative agonist binding is essential to accurately quantify agonist and drug actions.

SIGNIFICANCE STATEMENT

Some orthosteric agonists bind to multiple sites on a receptor, but current analytical methods to characterize such interactions are limited. Herein, we develop and validate operational models of agonism and allostereism for receptors with multiple orthosteric binding sites, and demonstrate that such models are essential to accurately quantify agonist and drug actions. These findings have important implications for the discovery and development of drugs targeting receptors such as the calcium-sensing receptor, which binds at least five calcium ions.

Introduction

The past 30 years have seen major advances in quantifying the relationship between receptor occupancy and response, with the operational model of agonism (Black and Leff, 1983) representing one of the most common analytical approaches. The operational model of agonism describes agonist effects based on agonist affinity [equilibrium dissociation constant of the orthosteric agonist (K_A)] and observed efficacy in a given test system. The latter is defined by a transducer ratio (τ),

This work was supported by the National Health and Medical Research Council of Australia [Project Grants APP1085143 (to K.L.), APP1138891 (to K.L. and K.J.G.), APP1084775 (to K.J.G.), and APP1127322 (to K.J.G.); Program Grant APP1055134 (to A.C.); and Senior Principal Research Fellowship APP1102950 (to A.C.)]; the Australian Research Council [Discovery Grant DP170104228 (to K.L. and K.J.G.), and Future Fellowships FT160100075 (to K.L.) and FT170100392 (to K.J.G.)]; and the Ministerio de Ciencia, Innovación y Universidades of Spain [Project Grant SAF2017-87199-R (to J.G.)].

<https://doi.org/10.1124/mol.119.118091>.

[§] This article has supplemental material available at molpharm.aspetjournals.org.

ABBREVIATIONS: AC265347, 1-(1,3-benzothiazol-2-yl)-1-(2,4-dimethylphenyl)ethanol; ACh, acetylcholine; Ca^{2+} , intracellular calcium; Ca^{2+}_o , extracellular calcium; calcimimetic B, R-1-(6-methoxy-4'-(trifluoromethyl)-3-biphenyl)-N-(R)-1-phenylethyl)ethanamine; CaSR, calcium-sensing receptor; DMEM, Dulbecco's modified Eagle's medium; DPFE, 1-(4-(2,4-difluorophenyl)piperazin-1-yl)-2-((4-fluorobenzyl)oxy)ethanone; E_m , maximal system response; E_{max} , maximum effect; GPCR, G protein-coupled receptor; HEK, human embryonic kidney; K_A , equilibrium dissociation constant of the orthosteric agonist; K_B , equilibrium dissociation constant of the allosteric ligand; LY2033298, 3-amino-5-chloro-6-methoxy-4-methyl-thieno[2,3-b]pyridine-2-carboxylic acid cyclopropylamide; M-5MPEP, 2-[2-(3-methoxyphenyl)ethyl]-5-methylpyridine; mAChR, muscarinic acetylcholine receptor; mGlu, metabotropic glutamate receptor; MPEP, 2-methyl-6-(2-phenylethynyl)pyridine; NAM, negative allosteric modulator; n_B , binding slope linking agonist concentration to receptor occupancy; n_H , Hill slope; τ , transducer slope linking agonist concentration to response; NPS2143, 2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-yl)propan-2-yl]amino]propoxy]benzonitrile; PAM, positive allosteric modulator; WT, wild type; VE-29, 2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-yl)propan-2-yl]amino]propoxy]benzonitrile.

which is a function of both tissue- and agonist-specific components; it is the ratio of the total receptor number and a transducer parameter that defines the avidity with which a given agonist-occupied receptor complex promotes the final observed pharmacological effect. As such, the operational model of agonism is a useful tool for quantifying agonism in a comparable manner across different test systems (Black and Leff, 1983), and has subsequently been extended or modified to also quantify effects of allosteric modulators and biased agonists (Leach et al., 2007, 2010; Kenakin, 2012).

The operational model of agonism has been most commonly applied to characterize the activity of agonists that display both rectangular hyperbolic or nonhyperbolic concentration-response curves, i.e., normally empirically characterized by Hill slopes that are equal to or different from unity, respectively. The key underlying assumption in the majority of instances to date where an agonist concentration-response curve displays a Hill slope significantly different from 1 has been ascribed in the most common form of the operational model to differences in the postreceptor machinery that transduces occupancy to response, i.e., through introduction of a so-called transducer slope (n) (Black et al., 1985). For instance, steep or shallow Hill slopes could arise due to changes in the sensitivity of one or more steps in a receptor's signal transduction mechanism, while the initial agonist-receptor binding event is assumed to be characterized by a simple hyperbolic one-to-one relationship. However, for ion channels and a number of G protein-coupled receptors (GPCRs), particularly the class C GPCR subfamily, nonhyperbolic concentration-response relationships can also arise from cooperative binding of multiple equivalents of the same endogenous agonist molecule prior to any subsequent processing of the stimulus by the cellular transduction machinery. For example, while a number of small molecule calcium-sensing receptor (CaSR) agonists produce responses characterized by Hill slopes close to unity (Cook et al., 2015; Keller et al., 2018), indicating a transducer slope equal to unity, it is also well established that CaSR responses to its endogenous activator, extracellular calcium (Ca_0^{2+}), and other divalent cations are characterized by extremely high Hill slopes, ranging from 2 to 4 (Brown, 1983; Davey et al., 2012; Leach et al., 2015). The most parsimonious explanation to account for these disparate observations is that the operational transducer slope linking CaSR agonist occupancy to response can adequately be described by a transducer slope equal to unity, which suggests that the cooperativity observed in response to activators such as Ca_0^{2+} ions arises at the level of binding, not function. This is also in accord with known pharmacological and structural studies of the CaSR that have identified multiple binding sites for Ca_0^{2+} ions (Geng et al., 2016). As a consequence, the classic operational model of agonism as applied to concentration-response curves of nonunit Hill slopes is suboptimal for such situations.

Herein, we sought to develop and evaluate an operational model of agonism that describes orthosteric agonist binding to multiple sites in a cooperative manner, referred to as the cooperative agonist operational model. The cooperative agonist operational model was superior to the original Black-Leff operational model of agonism in fitting Ca_0^{2+} -CaSR concentration-response data. We also extended this cooperative agonist operational model to incorporate allosteric modulation of the affinity and efficacy of an agonist that binds cooperatively to multiple sites. This operational model of allosterism with cooperative agonist binding was fitted to data describing the actions of CaSR positive allosteric

modulators (PAMs) and negative allosteric modulators (NAMs), and revealed that if cooperative agonist binding is not taken into consideration, under- or overestimates of PAM and NAM affinity and cooperativity can occur.

Materials and Methods

Materials. Dulbecco's modified Eagle's medium (DMEM), F12-In human embryonic kidney (HEK) T-REx cells, blasticidin S HCl, and FBS were obtained from Invitrogen (Carlsbad, CA), while hygromycin B was obtained from Roche (Mannheim, Germany). Fluo-8 AM was obtained from Abcam (Cambridge, MA).

CaSR-Expressing HEK293 Cell Lines. The generation of DNA and F12-In HEK T-REx cells stably expressing c-myc-tagged wild-type (WT) CaSR in pcDNA5/rt/TO have been described previously (Davey et al., 2012; Leach et al., 2016). F12-In HEK T-REx CaSR cells were maintained in DMEM containing 5% FBS, 200 $\mu\text{g}/\text{ml}$ hygromycin B, and 5 $\mu\text{g}/\text{ml}$ blasticidin S HCl. To generate a tetracycline-inducible F12-In HEK cell line stably expressing an N-terminally truncated CaSR, N-terminally truncated CaSR corresponding to amino acids 600–903 with an N-terminal influenza hemagglutinin signal peptide followed by a c-myc epitope and rhodopsin signal peptide in pcDNA3.1+ (Leach et al., 2016) was transferred to pcDNA5/rt/TO using BamHI and NotI restriction sites. F12-In HEK T-REx cells were seeded into 25 cm^2 flasks in DMEM containing 5% FBS and allowed to reach 80% confluency. Cells were transfected with 0.5 μg pcDNA5/rt/TO containing the N-terminally truncated CaSR plus 5 μg POG44 with lipofectamine 2000 (1:4 DNA:lipofectamine 2000) according to the manufacturer's instructions. The following day, cells were transferred to a T75 cm^2 flask, and 24 hours later DMEM was replaced with DMEM containing 5% FBS, 200 $\mu\text{g}/\text{ml}$ hygromycin, and 5 $\mu\text{g}/\text{ml}$ blasticidin S HCl. The selection DMEM was replaced every 3 days until untransfected cells had died (~10 days), and antibiotic-resistant cells were expanded and maintained in DMEM containing 5% FBS, 200 $\mu\text{g}/\text{ml}$ hygromycin, and 5 $\mu\text{g}/\text{ml}$ blasticidin S HCl. All cell lines were routinely tested for mycoplasma contamination using the Lonza MycoAlert mycoplasma detection kit.

Determination of WT and N-Terminally Truncated CaSR Cell Surface Expression Using Fluorescence-Activated Cytometry. F12-In HEK T-REx WT and N-terminally truncated CaSR-expressing cells were seeded at 80,000 cells per well into a 96-well plate and expression was induced with 100 ng/ml tetracycline overnight at 37°C. The following day, cells were harvested and washed in 1X PBS with 0.1% bovine serum albumin and 2 mM EDTA (wash buffer) by centrifugation (350g, 4°C for 3 minutes) before resuspension and 30-minute incubation in 100 μl blocking buffer (1X PBS, 5% bovine serum albumin, and 2 mM EDTA) containing 1 $\mu\text{g}/\text{ml}$ AF647-conjugated 9E10 made in-house as previously described (Cook et al., 2015). Cells were washed as previously described and resuspended in wash buffer containing propidium iodide. Live cell fluorescence was measured using a BD FACS Canto analyzer (Becton Dickinson).

Calcium Mobilization Assays. Cells were seeded in clear 96-well plates coated with poly-D-lysine (50 $\mu\text{g}/\text{ml}^{-1}$) at 80,000 cells per well and incubated overnight in the presence of 0 or 100 ng/ml $^{-1}$ tetracycline. The following day, cells were washed with assay buffer (150 mM NaCl, 2.6 mM KCl, 1.18 mM MgCl_2 , 10 mM D-Glucose, 10 mM HEPES, 0.1 mM CaCl_2 , 0.5% bovine serum albumin, and 4 mM probenecid at pH 7.4) and loaded with Fluo-8 AM (1 μM in assay buffer) for 1 hour at 37°C. Cells were washed with assay buffer prior to the addition of fresh assay buffer.

For all studies, each well was treated with a single agonist concentration. The release of intracellular calcium (Ca_i^{2+}) was measured at 37°C using FlexStation 1 or 3 (Molecular Devices, Sunnyvale, CA). Fluorescence was detected for 60 seconds at 490 nm excitation and 520 nm emission and the peak Ca_i^{2+} mobilization response (approximately 12 seconds after agonist addition) was used for the subsequent determination of the agonist response. Relative peak

fluorescence units were normalized to the fluorescence stimulated by 1 μ M ionomycin to account for differences in cell number and loading efficiency.

Model Derivation and Data Analysis. The derivation of operational models describing the effect of an agonist in the absence or presence of an allosteric modulator at a receptor with multiple agonist binding sites is presented in the Supplemental Appendix. The script input to use the two equations in the GraphPad Prism program is also presented in the Supplemental Appendix.

Data simulations were performed using the original Black-Leff operational model of agonism, referred to hereinafter as the Black-Leff

Data describing the interaction between glutamate and PAMs and NAMs at metabotropic glutamate receptor (mGlu) subtype 5, or between acetylcholine (ACh) and 3-amino-5-chloro-6-methoxy-4-methyl-thieno[2,3-b]pyridine-2-carboxylic acid cyclopropylamide (LY2033298) at the M_4 muscarinic acetylcholine receptor (mAChR), were fitted to our original operational model of allosterism (eq. 3) or to the new operational model of allosterism with cooperative agonist binding (eq. 4). For simplicity and for the purpose of fitting experimental data, eqs. 3–8 assume a single allosteric modulator binding site; therefore, they do not take into account modulator cooperative binding:

$$\text{Effect} = \frac{E_m \{ \tau_A [A] (K_B + \alpha \beta [B]) + \tau_B [B] [K_A] \}^{n_T}}{([A] K_B + K_A K_B + K_A [B] + \alpha [A] [B])^{n_T} + \{ \tau_A [A] (K_B + \alpha \beta [B]) + \tau_B [B] [K_A] \}^{n_T}} \quad (3)$$

$$\text{Effect} = \frac{E_m \{ \tau_A [A]^{n_B} (K_B + \alpha \beta [B]) + \tau_B [B] [K_A]^{n_B} \}^{n_T}}{([A]^{n_B} K_B + K_A^{n_B} K_B + K_A^{n_B} [B] + \alpha [A]^{n_B} [B])^{n_T} + \{ \tau_A [A]^{n_B} (K_B + \alpha \beta [B]) + \tau_B [B] [K_A]^{n_B} \}^{n_T}} \quad (4)$$

model (eq. 1), or a modified cooperative agonist operational model (eq. 2), where an additional slope [i.e., the binding slope linking agonist concentration to receptor occupancy (n_B)] was incorporated to take into account multiple agonist binding sites, and thus the steepness of the slope describing the agonist concentration-occupancy relationship:

$$\text{Effect} = \frac{E_m \tau_A^{n_T} [A]^{n_T}}{\tau_A^{n_T} [A]^{n_T} + ([A] + K_A)^{n_T}} \quad (1)$$

$$\text{Effect} = \frac{E_m \tau_A^{n_T} [A]^{n_B n_T}}{\tau_A^{n_T} [A]^{n_B n_T} + ([A]^{n_B} + K_A^{n_B})^{n_T}} \quad (2)$$

where $[A]$ is the agonist concentration, K_A is the agonist equilibrium dissociation constant; τ_A is an operational measure of agonist efficacy; E_m is the maximal system response; and n_T is the transducer slope linking agonist concentration to response.

For simplicity, the modified cooperative operational model of agonism (eq. 2) makes the following assumptions:

1. The receptor is either empty or fully occupied, and only the fully occupied receptor exerts an effect. The lack of partially occupied receptor molecules could arise if multiple agonist molecules bind simultaneously to the receptor, or if agonist molecules bind sequentially with high positive cooperativity. Thus, once one binding site is occupied, positive cooperativity drives occupancy of all other sites. The latter scenario is most likely; hence, this is why we have called this model the cooperative agonist operational model.
2. The model cannot discern cooperativity between the multiple binding sites, thus n_B may not be the true number of binding sites; therefore, n_B is a binding slope coefficient.
3. The K_A value is a geometric mean of the microscopic dissociation constants for each binding site.

The Eqs. 1 or 2 were fitted to agonist concentration response data in order to quantify agonist affinity and efficacy. When fitting eq. 2 to experimental data, the transducer slope was constrained to unity (see *Results* for validation of this assumption).

where K_A is the equilibrium dissociation constant of the orthosteric agonist, which was fixed in some instances to the affinity determined in radioligand binding assays (Mutel et al., 2000; Leach et al., 2010); K_B is the equilibrium dissociation constant of the allosteric ligand; τ_A and τ_B are the operational efficacies of the orthosteric agonist and allosteric ligand, respectively; α and β are the allosteric effects on orthosteric agonist affinity and efficacy, respectively (it should be noted that β is not a reciprocal efficacy cooperativity factor) (Leach et al., 2007; Giraldo, 2015); and $[A]$ and $[B]$ are the orthosteric agonist and allosteric ligand concentrations, respectively.

To fit the operational model of allosterism to data describing the interaction between Ca_o^{2+} and cinacalcet at the CaSR, the original operational model of allosterism shown by eq. 3 was simplified, because for a full agonist like Ca_o^{2+} (i.e., one that generates the maximal system response at submaximal receptor occupancies) $K_A \gg [A]$. Furthermore, because the CaSR's orthosteric agonist, Ca_o^{2+} , was present in the assay buffer, the contaminating agonist was included in the equations used to analyze CaSR PAM (cinacalcet) and NAM (2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]benzonitrile [NPS2143]) data (Keller et al., 2018). Therefore, data describing the interaction between Ca_o^{2+} and cinacalcet or NPS2143 at the CaSR were fitted to the original operational model of allosterism with the contaminating agonist (eqs. 5 and 6, respectively) or to an operational model of allosterism with cooperative agonist binding and contaminating agonist (eqs. 7 and 8, respectively):

$$\text{Effect} = \frac{E_m \{ [A + C] (K_B + \alpha \beta [B]) + \tau_B [B] [EC_{50}] \}^{n_T}}{[EC_{50}]^{n_T} (K_B + [B])^{n_T} + \{ [A + C] (K_B + \alpha \beta [B]) + \tau_B [B] [EC_{50}] \}^{n_T}} \quad (5)$$

where EC_{50} is the agonist concentration that elicits a half-maximal response, in which it should be noted that inclusion of $[EC_{50}]$ involves some simplifying assumptions that facilitate data fitting (Aurelio et al., 2009; Giraldo, 2015); $[C]$ is the contaminating agonist concentration; and all other parameters are as described for eq. 3:

$$\text{Effect} = \frac{E_m \{ [A + C] (K_B + \alpha \beta [B]) + \tau_B [B] [K_A] \}^{n_T}}{([A] K_B + K_A K_B + K_A [B] + \alpha [A + C] [B])^{n_T} + \{ [A + C] (K_B + \alpha \beta [B]) + \tau_B [B] [K_A] \}^{n_T}} \quad (6)$$

$$\text{Effect} = \frac{E_m \{ [A + C]^{n_B} (K_B + \alpha \beta [B]) + \tau_B [B] [EC_{50}]^{n_B} \}^{n_T}}{[EC_{50}]^{n_B n_T} (K_B + [B])^{n_T} + \{ [A + C]^{n_B} (K_B + \alpha \beta [B]) + \tau_B [B] [EC_{50}]^{n_B} \}^{n_T}} \quad (7)$$

Fig. 1. The n_T and n_B values differentially contribute to agonist concentration-response relationships. Simulations demonstrating the influence of n_T or n_B on concentration-response relationships for agonists with different efficacies (τ_A). Data were simulated using the cooperative agonist operational model (eq. 2), where the affinity of the agonist (K_A) is 1.2 mM and n_T and n_B are between 1 and 3. Curves through the data are the fits to a four-parameter Hill equation (eq. 9), where the parameters describing the fits are given in Table 1.

where EC_{50} , K_B , τ_B , α , β , $[A]$, $[B]$, $[C]$, and E_m are as described for eq. 5:

$$\text{Effect} = \frac{E_m \{ \tau_A [A + C]^{n_B} (K_B + \alpha \beta [B]) + \tau_B [B] [K_A]^{n_B} \}^{n_T}}{([A + C]^{n_B} K_B + K_A^{n_B} K_B + K_A^{n_B} [B] + \alpha [A + C]^{n_B} [B])^{n_T} + \{ \tau_A [A]^{n_B} (K_B + \alpha \beta [B]) + \tau_B [B] [K_A]^{n_B} \}^{n_T}} \quad (8)$$

where all other parameters are as described for eq. 4.

The Hill equation (Eq 9) was fitted to simulated data:

$$\text{Effect} = \frac{[A]^{n_H} E_{\max}}{[A]^{n_H} + EC_{50}^{n_H}} \quad (9)$$

where $[A]$ is the agonist concentration; $E_{\max}$ is the maximum agonist effect; and n_H is the Hill slope.

Nonlinear regression analysis was performed in GraphPad Prism 7 or 8. Potency, affinity, cooperativity, and efficacy parameters were

estimated as logarithms (Christopoulos, 1998). An extra sum of squares F test was used to determine whether data were fitted best when the Hill slope, binding slope, or transducer slope (n_H , n_B , or n_T , respectively) were significantly different from unity, where $P < 0.05$ was considered significant.

Results

The Contribution of Slope Factors to Agonist Concentration-Response Relationships. We first evaluated the contribution of the agonist binding slope (n_B) or transducer slope (n_T) to the concentration-response curve of two agonists with different efficacies by simulating variations in n_B or n_T using the cooperative agonist operational model (eq. 2). We specifically wanted to evaluate a system with cooperative agonist binding; therefore, we based our simulations on Ca_o^{2+} activation of the CaSR. The Ca_o^{2+} concentration-response relationship for the CaSR's best characterized physiologic role, inhibition of parathyroid hormone secretion, occurs over a Ca_o^{2+} concentration range of 0.8–1.5 mM with an EC_{50} value of ~1.2 mM (Brown, 1983). Thus, for these simulations, the affinity of the agonist (K_A) was assumed to be 1.2 mM and n_B or n_T were assumed to be between 1 and 3. Simulated data were subsequently fitted to a Hill equation (eq. 9). Unsurprisingly, increasing n_B or n_T increases the Hill slope of the agonist concentration-response curve (Fig. 1; Table 1). Furthermore, increasing n_T decreases agonist potency. Interestingly, the effect of n_B on agonist potency depends on the magnitude of n_T and τ_A . For instance, increasing n_B decreases agonist potency for higher efficacy agonists (τ_A 3). However, for lower efficacy agonists (τ_A 1), increasing n_B decreases agonist potency when $n_T \leq 1$, but increases agonist potency when $n_T \geq 2$.

We next sought to directly compare the influence of the binding or transducer slope by simulating concentration-response curves for agonists with varying efficacies using the Black-Leff operational model (eq. 1, which contains a transducer slope, n_T) and the cooperative agonist operational model (eq. 2, which contains transducer and binding slopes, n_T and n_B , respectively). As can be seen in Fig. 2 and Table 2, when n_T or n_B are equal to 1, variations in τ_A have an identical effect on empirical agonist concentration-response parameters (potency, Hill slope, or $E_{\max}$) regardless of the model. In contrast, when n_T or n_B are greater than 1, variations in τ_A result in major differences in the agonist

concentration-response profile predicted with the two different operational models of agonism. Specifically, the Black-Leff model predicts that high-efficacy agonists have greater potency relative to affinity (due to amplification of the steps between agonist binding and response), while for low-efficacy agonists, the EC_{50} value may be less than the K_A value for curves that possess nonunity Hill slopes. The latter was previously noted by Black et al. (1985). Furthermore, the Hill slope decreases alongside decreases in τ_A . In comparison, the

TABLE 1

Simulation of agonist concentration-response relationships upon changes in binding or transducer slopes and τ_A

Data were simulated using the cooperative agonist operational model (eq. 2) and a Hill equation (eq. 9) was fitted to simulated data to determine agonist potency, maximum effect, and Hill slope.

Parameter	eq. 2											
	n_B 0.5			n_B 1			n_B 2			n_B 3		
	pEC ₅₀	E_{max}	n_H	pEC ₅₀	E_{max}	n_H	pEC ₅₀	E_{max}	n_H	pEC ₅₀	E_{max}	n_H
τ_A 1												
n_T 0.5	4.8	51	0.3	3.9	50	0.7	3.4	50	1.3	3.3	50	2.0
n_T 1	3.5	51	0.5	3.2	51	1.0	3.1	51	2.0	3.0	51	3.0
n_T 2	2.6	51	0.6	2.8	51	1.3	2.8	51	2.4	2.9	51	3.5
n_T 3	2.2	52	0.7	2.6	52	1.4	2.7	52	2.9	2.8	52	4.1
τ_A 3												
n_T 0.5	5.2	66	0.3	4.1	65	0.6	3.5	64	1.3	3.3	64	1.9
n_T 1	4.2	76	0.5	3.5	76	1.0	3.2	76	2.0	3.1	76	3.0
n_T 2	3.7	90	0.8	3.3	90	1.5	3.1	91	3.3	3.1	91	4.9
n_T 3	3.6	96	1.1	3.3	97	2.1	3.1	97	4.7	3.0	97	6.0

pEC₅₀, agonist potency.

cooperative agonist operational model predicts that when $n_T = 1$, agonist EC₅₀ may approach but not be less than its K_A value, regardless of whether $n_B > 1$, and there is no effect of τ_A on the Hill slope of the agonist concentration-response curve (Fig. 2; Table 2).

Quantification of Experimentally Derived Agonist Concentration-Response Data. We next tested whether our simulations were recapitulated in a functional assay that measures CaSR activation. To do so, we measured Ca_v2⁺-mediated Ca_i2⁺ mobilization following titration of CaSR expression using a tetracycline inducible system. In the absence of tetracycline, the maximal response to Ca_v2⁺ is

approximately 50% of the maximal response obtained under full induction of receptor expression (100 ng/ml tetracycline). In this system, fitting a Hill equation (eq. 9) to both data sets indicated that the data were fitted best when the Hill slope was unchanged with different receptor expression levels, i.e., different magnitudes of τ_A ($P < 0.05$, extra sum-of-squares F test; data not shown). For the CaSR, the small molecule allosteric agonists 1-(1,3-benzothiazol-2-yl)-1-(2,4-dimethylphenyl)ethanol (AC265347) and *R*-1-(6-methoxy-4'-(trifluoromethyl)-3-biphenyl)-*N*-(*R*)-1-phenylethyl)ethanamine (calcimimetic B) activate the CaSR with a Hill slope of 1

Fig. 2. Cooperative agonist binding influences agonist concentration-response relationships. Simulations demonstrating the influence of agonist efficacy (τ_A) on agonist concentration-response relationships when the slope is governed by the transducer slope (n_T , Black-Leff operational model of agonism) or the agonist binding slope (n_B , cooperative agonist operational model). Data were simulated using the Black-Leff model (eq. 1) or the cooperative agonist operational model (eq. 2), where the affinity of the agonist (K_A) is 1.2 mM and n_T and n_B are between 1 and 3. Curves through the data are the fits to a Hill equation (eq. 9), where the parameters describing the fits are given in Table 2.

TABLE 2
Simulation of agonist concentration-response relationships upon changes in binding or transducer slopes and τ_A
Data were simulated using the Black-Leff model (eq. 1) or the cooperative agonist operational model (eq. 2) and a Hill equation (eq. 9) was fitted to simulated data to determine agonist potency, maximum effect, and Hill slope.

τ_A	eq. 1; n_T 1			eq. 1; n_T 3			eq. 2; n_T 1, n_B 1			eq. 2; n_T 1, n_B 3			eq. 2; n_T 3, n_B 3		
	pEC ₅₀	E _{max}	n _H	pEC ₅₀	E _{max}	n _H	pEC ₅₀	E _{max}	n _H	pEC ₅₀	E _{max}	n _H	pEC ₅₀	E _{max}	n _H
100	4.9	99	1.0	4.9	100	3.0	4.9	99	1.0	3.6	99	3.0	3.6	100	8.9
10	4.0	91	1.0	3.9	100	2.7	4.0	91	1.0	3.3	91	3.0	3.2	100	7.6
1	3.2	51	1.0	2.6	50	1.5	3.2	51	1.0	3.0	51	3.0	2.8	51	4.5
0.3	3.0	24	1.0	2.4	3.0	1.4	3.0	24	1.0	3.0	24	3.0	2.7	3.0	3.9
0.1	3.0	9.0	1.0	2.3	0.1	1.4	3.0	9.0	1.0	3.0	9.0	3.0	2.7	0.1	3.8

pEC₅₀, agonist potency.

(Cook et al., 2015; Keller et al., 2018). Similarly, when cooperative agonist binding is prevented by removal of the CaSR's N-terminal domain, and consequently the primary Ca_o²⁺ binding sites, the Hill slope for Ca_o²⁺ is not significantly different from unity (as shown subsequently). This provides experimental evidence that the CaSR's transducer slope is equal to unity, and that the steep Hill slopes observed for Ca_o²⁺ at the full-length CaSR thus likely arise from a binding slope greater than 1. Thus, when fitting CaSR experimental data to the cooperative agonist operational model, n_T was constrained to unity.

When the data were fitted to the classic Black-Leff model, the estimated K_A value was 0.2 mM (Fig. 3A; Table 3). In comparison, the cooperative agonist operational model yielded a K_A estimate of 1.1 mM, which is in close agreement with the EC₅₀ value (1.2 mM) of Ca_o²⁺ for suppressing parathyroid hormone release (Brown, 1983) and Ca_o²⁺ affinity estimates for the CaSR extracellular domain determined using spectroscopic approaches (Huang et al., 2009; Zhang et al., 2014). For both analyses, data were fitted best when the binding slope (cooperative agonist operational model) or transducer slope (Black-Leff model) were different from unity ($P < 0.05$, extra sum of squares F test).

To further validate our simulations in a functional assay, we next sought to quantify the affinity and efficacy of a CaSR

partial agonist. To do so, we took advantage of observations that in comparison with at the WT CaSR (Fig. 3B), Ca_o²⁺ acting via the 7 transmembrane domain is a partial agonist at an N-terminally truncated CaSR (depicted in Fig. 3C) relative to the extracellular trivalent gadolinium cation (Fig. 3D). The fluorescence-activated cytometry analysis confirmed cell surface expression of the WT and N-terminally truncated CaSR (Supplemental Fig. 1). We quantified Ca_o²⁺ affinity and efficacy at the N-terminally truncated CaSR using the original Black-Leff model or the cooperative agonist operational model (Table 3). In both instances, data were best fitted when the binding slope (the cooperative agonist operational model) or transducer slope (the Black-Leff model) were not different from unity ($P < 0.05$, extra sum of squares F test), which is consistent with a reduction in positively cooperative Ca_o²⁺ binding, as would be expected upon removal of the four primary Ca_o²⁺ binding sites located in the N-terminal domain (Geng et al., 2016). Thus, the parameters determined at the N-terminally truncated receptor were identical regardless of the equation used to analyze the data. The Ca_o²⁺ affinity and cooperativity estimates at the N-terminally truncated receptor were compared with those determined at the full-length WT CaSR, indicating a reduction in Ca_o²⁺ affinity at the N-terminally truncated receptor in comparison with WT (Table 3), again consistent with removal of the primary

Fig. 3. Ca_o²⁺-CaSR concentration-response relationships fit well to the cooperative agonist operational model. (A) Ca_o²⁺-mediated Ca_i²⁺ mobilization at the WT CaSR following overnight receptor induction with 100 ng/ml tetracycline (tet) or in the absence of tetracycline. Data are mean + S.D. from four independent experiments performed in duplicate. Curves through the data are the fits to the Black-Leff model (blue line) or the cooperative agonist operational model (red line), where the parameters describing the fits are given in Table 3. Although both models fit the data, the cooperative agonist operational model more accurately predicts the expected affinity of Ca_o²⁺ at the CaSR (Table 3). (B) Extracellular trivalent gadolinium (Gd³⁺) and Ca_o²⁺ concentration-response curves at the WT CaSR following overnight receptor induction with 100 ng/ml tetracycline. Data are mean + S.D. from four independent experiments performed in duplicate. Curves through the data are the fits to a four-parameter Hill equation. (C) N-terminally truncated CaSR snake diagram. (D) Gd³⁺ and Ca_o²⁺ concentration-response curves at an N-terminally truncated CaSR following overnight receptor induction with 100 ng/ml tetracycline. Data are mean + S.D. from five independent experiments performed in duplicate. Curves through the data are the fits to the cooperative agonist operational model, where the parameters describing the fits are given in Table 3.

TABLE 3

Quantification of Ca_o^{2+} affinity and efficacy for CaSR-Ca_i^{2+} mobilization using the operational model of agonism

Ca_o^{2+} concentration-response curves were generated at the WT receptor following overnight incubation of cells with or without 100 ng/ml tetracycline to induce receptor expression. For N-terminally truncated CaSRs, Ca_o^{2+} and Gd^{3+} concentration-response curves were generated upon induction of expression with 100 ng/ml tetracycline, where Ca_o^{2+} is a partial agonist and Gd^{3+} is a full agonist. The Black-Leff model (eq. 1) or the cooperative agonist operational model (eq. 2) was fitted to data to determine agonist affinity, efficacy, and transducer or binding slope.

Parameter	WT		N-terminally truncated CaSR	
	eq. 1	eq. 2	eq. 1	eq. 2
pK_A [K_A (mM)]	3.7 ± 0.3 (0.2)	3.0 ± 0.1 (1.0)	2.3 ± 0.2 (5.0)	2.3 ± 0.2 (5.0)
$\text{Log } \tau_A$ (τ_A)	100 ng/ml tet: 0.2 ± 0.1 (1.6) 0 tet: -0.01 ± 0.01 (1.0)	100 ng/ml tet: 1.2 ± 0.2 (16) 0 tet: -0.1 ± 0.1 (0.8)	0.2 ± 0.1 (1.6)	0.2 ± 0.1 (1.6)
n	6.0 ± 3.0^a	2.0 ± 0.3^a	1.0^b	1.0^b

Dfd, degrees of freedom denominator; Dfn, degrees of freedom numerator; $\text{Log } \tau_A$ (τ_A), efficacy; n , transducer or binding slope; pK_A (K_A), agonist affinity; tet, tetracycline.

^aAn F test determined that data were fitted best when the binding or transducer slopes were different from unity. The F data used to test the hypothesis that n differed from 1 were the following: eq. 1 $P < 0.0001$, F [Dfn, Dfd] 48.57 (1, 74); and eq. 2 $P < 0.0001$, F [Dfn, Dfd] 45.78 (1, 74).

^bAn F test determined that data were fitted best when the binding or transducer slopes were not different from unity. The F data used to test the hypothesis that n differed from 1 were the following: eq. 1 $P < 0.2282$, F [Dfn, Dfd] 1.470 (1, 101); and eq. 2 $P < 0.5332$, F [Dfn, Dfd] 0.3910 (1, 101).

Ca_o^{2+} binding sites. However, due to a lower estimate of Ca_o^{2+} efficacy at the WT receptor when WT data were analyzed using the Black-Leff model, only the cooperative agonist operational model accurately quantified a reduction in Ca_o^{2+} efficacy at the N-terminally truncated receptor in comparison with at the WT receptor. This is consistent with a lower Ca_o^{2+} E_{max} value at the N-terminally truncated receptor (~60% of the maximum response stimulated by extracellular trivalent gadolinium) in comparison with WT (~100% extracellular trivalent gadolinium E_{max}) (Table 3). Thus, only the cooperative agonist operational model accurately estimated Ca_o^{2+} partial agonism at the N-terminally truncated receptor.

Quantifying Allosteric Interactions in Systems with Different Degrees of Cooperative Agonist Binding.

Having established that the cooperative agonist operational model best fitted our Ca_o^{2+} -WT CaSR concentration-response curves with Hill slopes greater than 1, we next extended this model to allow for quantification of allosteric modulation of an agonist response. The operational model of agonism and allosterism (Leach et al., 2007, 2010) (referred to herein as the original operational model of agonism and allosterism), which takes into account the allosteric effects on agonist affinity and efficacy, combines the allosteric ternary complex models developed by Stockton et al. (1983) and Ehlert (1988) and the Black-Leff operational model of agonism. In our original model (Leach et al., 2007), the allosteric modulator can also possess intrinsic efficacy. Introduction of a slope in that model once again assumed that the slope linked occupancy to response, not to the original binding events, which were assumed to be described as simple one-to-one hyperbolic functions. Therefore, we adapted this operational model of allosterism to account for cooperative agonist binding, referred to hereinafter as the operational model of allosterism with cooperative agonist binding. To validate this operational model of allosterism with cooperative agonist binding, we reanalyzed existing data demonstrating positive and negative allosteric modulation at three model GPCRs with different agonist Hill slopes: CaSR (a class C GPCR where the primary endogenous agonist, Ca_o^{2+} , has a Hill slope of 2–4), mGlu_5 (a class C GPCR where the primary endogenous agonist, L-glutamate, has a Hill slope of ~1.8) (Sengmany and Gregory, 2016), and M_4 mAChR (a class A GPCR where the endogenous agonist, acetylcholine, has a Hill slope of 1) (Leach et al., 2010, 2011) (Supplemental Fig. 2). In all instances, n_T was assumed to be unity and all allosteric

modulators were assumed to bind to a single site (i.e., the modulator binding slope is unity).

For the CaSR, we analyzed allosteric modulation of Ca_o^{2+} by cinacalcet (PAM) or NPS2143 (NAM) (Leach et al., 2016) with the original operational model of agonism and allosterism with contaminating (i.e., ambient buffer) agonist (eqs. 5 or 6, respectively) and the newly derived operational model of allosterism with cooperative agonist binding and contaminating agonist (eqs. 7 or 8, respectively) (Fig. 4). Similar to our analysis of agonist concentration-response curves, data were fitted best when the binding slope (operational model of allosterism with cooperative agonist binding) or transducer slope (original operational model of agonism and allosterism) was different from unity ($P < 0.05$, extra sum of squares F test). Compared with the original operational model of agonism and allosterism, the estimated affinity for Ca_o^{2+} determined using the operational model of allosterism with cooperative agonist binding (1.4 mM) (Table 4) was once again closer to the assumed Ca_o^{2+} affinity based on its EC_{50} value for suppression of parathyroid hormone release (1.2 mM) and quantification of the Ca_o^{2+} K_A at the extracellular domain using spectroscopic approaches (3–5 mM) (Huang et al., 2009; Zhang et al., 2014). Furthermore, the estimated affinity and negative cooperativity of NPS2143 were greater (5.5- and 35-fold, respectively) when cooperative agonist binding was factored into the analysis (Table 4). For the PAM, cinacalcet,

Fig. 4. Allosteric modulation at the CaSR is fitted well by an operational model of allosterism with cooperative agonist binding. Allosteric modulation of Ca_o^{2+} -mediated Ca_i^{2+} mobilization at the CaSR by NPS2143 (NAM) or cinacalcet (PAM). Data were previously published (Leach et al., 2016) and are mean $\pm$ S.D. from at least 11 independent experiments performed in duplicate. Curves through the data are the fits to the operational model of allosterism with cooperative agonist binding and contaminating agonist (eq. 7 for cinacalcet and eq. 8 for NPS2143), where the parameters describing the fits are given in Table 4.

TABLE 4

Comparison of parameters describing CaSR allosteric interactions analyzed with different allosteric models

CaSR allosteric interactions with Ca_0^{2+} in Ca_i^{2+} mobilization assays were analyzed with the original operational model of agonism and allosterism (eqs. 5 or 6) vs. the operational model of allosterism with cooperative agonist binding (eqs. 7 or 8) to determine Ca_0^{2+} potency, efficacy, and affinity; modulator affinity, cooperativity, and transducer or binding slope; and maximum system response.

Parameter	Ca_0^{2+} vs. Cinacalcet		Ca_0^{2+} vs. NPS2143	
	eq. 5	eq. 7	eq. 6	eq. 8
pEC ₅₀	3.3 ± 0.01	3.3 ± 0.01	n.d.	n.d.
pK _A [K_A (mM)]	n.d.	n.d.	3.6 ± 0.2 (0.3)	2.9 ± 0.1 (1.3)
pK _B [K_B (μM)]	6.3 ± 0.04 (0.5)	5.8 ± 0.1 (1.6)	6.6 ± 0.04 (0.3)	7.3 ± 0.1 (0.05)
Log τ_A (τ_A)	n.d.	n.d.	0.2 ± 0.1 (1.6)	1.8 ± 0.1 (63)
Log τ_B (τ_B)	n.a. (0)	n.a. (0)	n.a. (0)	n.a. (0)
Log $\alpha\beta$ ($\alpha\beta$)	0.5 ± 0.01 (3.2)	1.4 ± 0.1 (25)	-0.2 ± 0.1 (0.6)	-1.7 ± 0.1 (0.02)
n	2.8 ± 0.1 ^a	2.8 ± 0.1 ^a	12 ± 4.0 ^a	3.5 ± 0.2 ^a
E_m (% ionomycin)	79 ± 1.0	80 ± 1.0	78 ± 1.0	80 ± 2

Dfd, degrees of freedom denominator; Dfn, degrees of freedom numerator; E_m , maximum system response; Log $\alpha\beta$ ($\alpha\beta$), modulator cooperativity; Log τ_A (τ_A), Ca_0^{2+} efficacy; Log τ_B (τ_B), modulator efficacy; Ca_0^{2+} efficacy; n , transducer or binding slope; n.a., no agonist activity [log τ_B fixed to -100 (τ_B 0)]; n.d., not determined; pEC₅₀, Ca_0^{2+} potency; pK_A (K_A), Ca_0^{2+} affinity; pK_B (K_B), modulator affinity.

^aAn F test determined that data were fitted best when the transducer or binding slopes were different from unity. The F data used to test the hypothesis that n differed from 1 were the following: eq. 5 cinacalcet $P < 0.0001$, F [(Dfn, Dfd) 1249 (1, 2429)]; eq. 5 NPS2143 $P < 0.0001$, F [(Dfn, Dfd) 1022 (1, 908)]; eq. 7 cinacalcet $P < 0.0001$, F [(Dfn, Dfd) 1241 (1, 2429)]; and eq. 7 NPS2143 $P < 0.0001$, F [(Dfn, Dfd) 504.5 (1, 907)].

the operational model of allosterism with cooperative agonist binding yielded a 3-fold lower affinity estimate but an 8-fold greater magnitude of positive cooperativity.

We next analyzed allosteric modulation of glutamate at mGlu₅ (eqs. 3 or 4) by a representative full NAM (2-methyl-6-(2-phenylethynyl)pyridine [MPEP]) that completely inhibits glutamate-mediated activation of Ca_i^{2+} mobilization, a partial NAM (2-[2-(3-methoxyphenyl)ethynyl]-5-methylpyridine [M-5MPEP]) that only partially inhibits glutamate-mediated activation of Ca_i^{2+} mobilization (Sengmany et al., 2019), a pure PAM (N-(1,3-Diphenyl-1H-pyrazolo-5-yl)-4-nitrobenzamide [VU-29]), and a mixed PAM-agonist (1-(4-(2,4-difluorophenyl)piperazin-1-yl)-2-((4-fluorobenzyl)oxy)ethanone [DPFE]) (Sengmany et al., 2017). Similar to analyses at the CaSR, all data were fitted best when the binding slope (operational model of allosterism with cooperative agonist binding) or transducer slope (original operational model of agonism and allosterism) was different from unity ($P < 0.05$, extra sum of squares F test). However, for each modulator, the affinity and cooperativity estimates were similar (within 3-fold) irrespective of the analytical model applied (Fig. 5; Table 5). Therefore, although the glutamate-mGlu₅ concentration-response relationship has a Hill slope greater than unity, quantification of allosteric interactions at mGlu₅ is largely unaffected by whether the empirical slope is assumed to be determined by the transducer slope or the agonist binding slope.

For the M₄ mAChR, we analyzed previously published positive allosteric modulation of ACh by the PAM agonist LY2033298 in guanosine 5'-O-(3-[³⁵S]thio)triphosphate binding assays (Leach et al., 2010) (eqs. 3 or 4). As expected, in the absence of cooperative ACh binding at the M₄ mAChR, data for the interaction between ACh and LY2033298 were fitted best by both operational models of agonism and allosterism when the slope was not different from unity ($P < 0.05$, extra sum of squares F test); therefore, both equations yielded identical estimates of affinity and cooperativity (Fig. 6; Table 6).

We next sought to establish why quantification of PAM and NAM affinity and cooperativity were not greatly affected by

the assignment of the slope at mGlu₅, where the glutamate Hill slope is greater than unity. To do so, we simulated the interaction between an orthosteric agonist and a NAM or PAM with the operational model of allosterism with cooperative agonist binding and analyzed the simulated data with the original operational model of agonism and allosterism. For these simulations, orthosteric agonist affinity (1 μM), τ_A (10), and modulator affinity (10 nM) were held constant, and different magnitudes of positive or negative cooperativity were examined alongside changes in the magnitude of cooperative agonist binding. Consistent with our analysis of mGlu₅ allosteric interaction data, when the agonist binding

Fig. 5. Allosteric modulation at mGlu₅ is fitted well by an operational model of allosterism with cooperative agonist binding. Allosteric modulation of glutamate-mediated Ca_i^{2+} mobilization at mGlu₅ by MPEP (full NAM), M-5MPEP (partial NAM), VU-29 (PAM), and DPFE (ago-PAM). Data were previously published (Sengmany et al., 2017, 2019) and are mean ± S.D. from at least three independent experiments performed in duplicate previously published. Curves through the data are the fits to the operational model of allosterism with cooperative agonist binding (eq. 4), where the parameters describing the fits are given in Table 5.

TABLE 5

Comparison of parameters describing mGlu₅ allosteric interactions analyzed with different allosteric modelsmGlu₅ allosteric interactions with glutamate in Ca²⁺ mobilization assays were analyzed with the original operational model of agonism and allosterism (eq. 3) or the operational model of allosterism with cooperative agonist binding (eq. 4) to determine modulator affinity, glutamate or modulator efficacy, respectively, cooperativity, transducer or binding slopes, and maximum system response.

Parameter	Glutamate vs. MPEP ^a		Glutamate vs. VU-29 ^b		Glutamate vs. DPPE ^b	
	eq. 3	eq. 4	eq. 3	eq. 4	eq. 3	eq. 4
pK_A [K_A (μ M)]	6.2 (0.6) ^c	6.2 (0.6) ^c	6.2 (0.6) ^c	6.2 (0.6) ^c	6.2 (0.6) ^c	6.2 (0.6) ^c
pK_B [K_B (μ M)]	7.9 $\pm$ 0.1 (0.01)	8.4 $\pm$ 0.1 (0.004)	6.8 $\pm$ 0.2 (0.2)	6.8 $\pm$ 0.2 (0.2)	6.0 $\pm$ 0.3 (1.0)	5.6 $\pm$ 0.1 (2.5)
$\log \tau_A$ (τ_A)	0.7 $\pm$ 0.1 (5.0)	1.0 $\pm$ 0.2 (10)	0.6 $\pm$ 0.1 (3.9)	0.6 $\pm$ 0.2 (4.0)	0.6 $\pm$ 0.1 (4.0)	0.8 $\pm$ 0.1 (6.3)
$\log \tau_B$ (τ_B)	n.a. (0)	n.a. (0)	n.a. (0)	n.a. (0)	-0.2 $\pm$ 0.1 (0.6)	-0.4 $\pm$ 0.1 (0.4)
$\log \alpha\beta$ ($\alpha\beta$)	-100 ($\sim$ 0) ^d	-100 ($\sim$ 0) ^d	-0.5 $\pm$ 0.1 (0.3)	-0.8 $\pm$ 0.2 (0.2)	0.3 $\pm$ 0.03 (2.0)	0.6 $\pm$ 0.1 (4.0)
n	1.7 $\pm$ 0.2 ^e	1.5 $\pm$ 0.2 ^e	2.0 $\pm$ 0.2 ^e	1.6 $\pm$ 0.2 ^e	1.2 $\pm$ 0.1 ^e	2.5 $\pm$ 0.7 ^e
E_m (% glutamate)	106 $\pm$ 6.0	111 $\pm$ 6.0	107 $\pm$ 6.0	123 $\pm$ 1.0	108 $\pm$ 3.0	105 $\pm$ 2.0

Dfd, degrees of freedom denominator; Dfn, degrees of freedom numerator; E_m , maximum system response; $\log \tau_A$ (τ_A), modulator cooperativity; $\log \tau_B$ (τ_B), modulator efficacy; n , transducer or binding slope; n.a., no agonist activity ($\log \tau_B$ fixed to -100 (τ_B 0)); pK_A (K_A), agonist affinity; pK_B (K_B), modulator affinity.

^aValues derived by fitting previously reported experimental data (Sengmany et al., 2019).

^bValues derived by fitting previously reported experimental data (Sengmany et al., 2019).

^cThe pK_A value was fixed to that determined in radioligand binding assays (Mutez et al., 2000).

^dThe $\log \alpha\beta$ value was fixed to -100 due to complete inhibition of glutamate-mediated stimulation of Ca²⁺ mobilization, reflecting high negative cooperativity.

^eAn F test determined that data were fitted best when the transducer or binding slopes were different from unity. The F data used to test the hypothesis that n differed from 1 were the following: eq. 3 MPEP P = 0.0003, F (Dfn, Dfd) 13.46 (1, 149); eq. 3 M-5MPEP P = 0.0007, F (Dfn, Dfd) 11.96 (1, 126); eq. 3 VU-29 P = 0.0015, F (Dfn, Dfd) 10.45 (1, 144); eq. 3 DPPE P = 0.0062, F (Dfn, Dfd) 7.587 (1, 294); eq. 4 MPEP P = 0.0002, F (Dfn, Dfd) 14.33 (1, 149); eq. 4 M-5MPEP P < 0.0001, F (Dfn, Dfd) 22.26 (1, 126); eq. 4 VU-29 P = 0.0003, F (Dfn, Dfd) 13.97 (1, 144); and eq. 4 DPPE P < 0.0001, F (Dfn, Dfd) 24.13 (1, 294).

Fig. 6. Allosteric modulation at the M₄ mAChR is fitted well by an operational model of allosterism with no cooperative agonist binding. Positive modulation of ACh-mediated guanosine 5'-O-(3-[(³⁵S)]thio)triphosphate ([³⁵S]GTPγS) binding by LY2033298 (ago-PAM) at the M₄ mAChR. Data were previously published (Leach et al., 2010) and are mean $\pm$ S.D. from at least three independent experiments performed in duplicate. Curves through the data are the fits to the operational model of allosterism with cooperative agonist binding (eq. 4), where the equation was fitted best when n = 1 (i.e., no cooperative agonist binding). The parameters describing the fits are given in Table 6.

slope ranged from 1 to 2 the affinity of NAMs and PAMs estimated using the original operational model of agonism and allosterism fell within $\sim$ 3-fold of the affinity simulated with the operational model of allosterism with cooperative agonist binding. Furthermore, only the affinity of the full NAM (where $\alpha\beta$ is assumed to approach zero) fell outside this 3-fold window once the agonist binding slope exceeded 2 (Fig. 7A). Similarly, when analyzed with the original operational model of agonism and allosterism, the $\alpha\beta$ values (0.1–10) were within a 3-fold range of simulated data when n_T ranged from 1 to 2. However, where the magnitude of cooperativity exceeded 10 for a PAM, or 0.1 for a NAM, the influence of cooperative agonist binding becomes more pronounced (Fig. 7B). These simulations confirm that the assignment of n to a transducer or binding slope would not be expected to greatly influence quantification of mGlu₅ allosteric modulation of glutamate for modulators with moderate cooperativity, which is consistent with our Ca²⁺ mobilization data.

Discussion

In the current study, we have assessed operational models of agonism and allosterism that account for receptors whose agonists bind multiple binding sites in a cooperative manner. The modified models accurately fit experimental data at an exemplar GPCR, the CaSR, which has high sensitivity for Ca²⁺ due to multiple Ca²⁺ binding sites that are linked in a positively cooperative manner. We show that agonist Hill slopes that differ from unity and remain unchanged by alterations in receptor expression levels or cellular coupling efficiencies (i.e., where τ_A differs) may be indicative of cooperative agonist binding. We demonstrate that if a steep Hill slope such as that observed at the CaSR is attributed to the transducer slope rather than to the agonist binding slope, the Black-Leff operational model of agonism underestimates agonist efficacy and overestimates agonist affinity. Extension to allosteric interactions shows the importance of accounting for cooperative agonist binding, since different models fitted to the same allosteric interaction data yield divergent modulator affinity and cooperativity estimates. For instance, the original operational model of agonism and allosterism estimates lower CaSR PAM and NAM cooperativity values and higher or lower

TABLE 6

Comparison of parameters describing M_4 mAChR allosteric interactions analyzed with different allosteric models

M_4 mAChR LY2033298 interactions with ACh in guanosine 5'-O-(3-[35 S]thio) triphosphate binding assays were analyzed with the original operational model of agonism and allosterism (eq. 3) or the operational model of allosterism with cooperative agonist binding (eq. 4) to determine agonist or modulator affinity, agonist or modulator efficacy, cooperativity, transducer or binding slopes, and maximum system response. Values obtained from fitting eqs. 3 and 4 to the data were identical; therefore, they are only presented in a single column.

Parameter	ACh vs. LY2033298 (eqs. 3 and 4) ^a
pK_A [K_A (μ M)]	6.0 (1.0) ^b
pK_B [K_B (μ M)]	5.9 ± 0.3 (1.3)
$\text{Log } \tau_A$ (τ_A)	0.9 ± 0.1 (7.9)
$\text{Log } \tau_B$ (τ_B)	0.5 ± 0.2 (3.2)
$\text{Log } \alpha\beta$ ($\alpha\beta$)	0.7 ± 0.3 (5.0)
n	1.0 ^c
E_m (% ACh maximum)	112 ± 5.0

Dfd, degrees of freedom denominator; Dfn, degrees of freedom numerator; E_m , maximum system response; $\text{Log } \alpha\beta$ ($\alpha\beta$), cooperativity; $\text{Log } \tau_A$ (τ_A), agonist efficacy; $\text{Log } \tau_B$ (τ_B), modulator efficacy; n , transducer or binding slope; pK_A (K_A), agonist affinity; pK_B (K_B), modulator affinity.

^aData analyzed are from Leach et al. (2010).

^bThe pK_A value was fixed to that determined in radioligand binding assays (Leach et al., 2010).

^cAn F test determined that data were fitted best when the transducer or binding slopes were not different from unity. The F data used to test the hypothesis that n differed from 1 were the following: eq. 3 $P = 0.5766$, F [(Dfn, Dfd) 0.3129 (1, 172)]; and eq. 4 $P = 0.4541$, F [(Dfn, Dfd) 0.5629 (1, 172)].

affinity values, respectively. Data simulations support these findings and demonstrate that the impact of cooperative binding on estimates of modulator affinity and cooperativity is more pronounced as the magnitude of modulator cooperativity or cooperative agonist binding is increased. This was evidenced by our demonstration that for mGlu₅, where the glutamate Hill slope is ~ 1.8 , differences in affinity and cooperativity are within the margin of experimental error (~ 3 -fold range). Accordingly, for agonist-receptor concentration-response relationships with Hill slopes equal to unity, it does not matter whether the slope is governed by the transducer slope or the agonist binding slope.

The operational models of agonism and allosterism with cooperative agonist binding have important practical uses for analyzing data at receptors that possess multiple agonist binding sites. This is particularly true for the CaSR, but also for ion channels and other GPCRs where agonist binding coefficients differ from unity, such as GPR39, which binds at least two Zn^{2+} ions and responds to Zn^{2+} with a Hill slope of 2–3 (Storjohann et al., 2008; Sato et al., 2016). Similarly, cooperative binding can occur across a GPCR dimer, which may account for the steep Hill slope at mGlu₅ demonstrated in the present study. For instance, the mGlu₂ orthosteric agonist

(1*S*,2*S*,5*R*,6*S*)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740) stabilizes conformational rearrangements of a metabotropic glutamate receptor subtype 2 and 4 heterodimer (mGlu₂-mGlu₄) with a shallow Hill slope (Moreno Delgado et al., 2017), which is increased to unity when LY354740 is prevented from binding to the mGlu₂ or mGlu₄ orthosteric binding site in the dimer. In contrast, the glutamate E_{max} value is reduced when it can bind to only one of the orthosteric sites in the heterodimer (Moreno Delgado et al., 2017). These findings indicate negative (LY354740) and positive (glutamate) cooperativity across the dimer, respectively. Negative cooperative binding has also been demonstrated at several class A GPCRs dimers, including the 5-hydroxytryptamine_{2A}, A₃ adenosine, H₃ histamine, and D₂ dopamine receptors (Sinkins and Wells, 1993; Vivo et al., 2006; Brea et al., 2009; May et al., 2011). Accurate quantification of ligand affinity, efficacy, and cooperativity at such receptors using functional assays is critical, particularly where radioligand binding-based methods are not available. Indeed, there are no commercially available radioligands for the CaSR, thus pharmacological characterization, and indeed drug discovery at this receptor has generally relied upon functional measures of receptor activity to quantify drug actions. However, it must be noted that experimentally derived pharmacological data for agonists with steep Hill slopes will likely only be fitted to the cooperative agonist operational model and the operational model of allosterism with cooperative agonist binding when one of the binding or transducer slopes (n_B or n_T) is known and constrained as such. This was a key advantage of analyzing pharmacological data at the CaSR, where we showed experimentally that the transducer slope is 1.

Our findings have important implications for past and present drug discovery efforts at class C GPCRs and beyond. Establishing structure-activity relationship profiles that dictate drug affinity and cooperativity is essential for predicting drug efficacy in vivo. However, underestimates of cooperativity at class C GPCRs with cooperative agonist binding may explain previous observations that class C GPCR allosteric modulators have limited cooperativity when compared with their class A GPCR counterparts. For example, PAMs with $\alpha\beta$ values >100 have been reported for class A GPCRs (Leach et al., 2010; Abdul-Ridha et al., 2014), whereas for the CaSR potentiation is at most 5-fold for many modulators (Cook et al., 2015; Leach et al., 2016; Diepenhorst et al., 2018). Thus, for GPCRs with cooperative agonist binding, larger differences between modulator cooperativities were likely previously unappreciated. This is important because allosteric modulator

Fig. 7. Modulator affinity and cooperativity are influenced by assignment of the slope in the operational model of allosterism. Simulations demonstrating the influence of the agonist binding slope on the estimated modulator affinity and cooperativity when interaction data are analyzed using the original operational model of allosterism. Interaction data between an orthosteric agonist and a NAM or PAM were simulated with the operational model of allosterism with cooperative agonist binding. Orthosteric agonist affinity (1 μ M), τ_A (10), and modulator affinity (10 nM) were held constant; different magnitudes of positive or negative cooperativity were examined alongside changes in the magnitude of cooperative agonist binding. The simulated data were analyzed with the original operational model of allosterism, and $\text{log } K_B$ (A) or $\text{log } \alpha\beta$ (B) estimates were plotted against the agonist binding slope.

cooperativity can predict likely clinical efficacy or adverse effect liability. Inaccurate estimation of allosteric modulator affinity or cooperativity due to a failure to consider cooperative agonist binding likely also impacts interpretation of structure-function studies. If cooperativity values are narrowed, then more subtle effects of mutations on modulator cooperativity may have been missed.

In conclusion, we have validated a method for quantifying agonist and allosteric modulator actions at receptors possessing multiple agonist binding sites that interact in a cooperative manner. Our operational models of agonism and allosterism with cooperative agonist binding more accurately quantify the actions of both orthosteric and allosteric drugs acting at GPCRs with cooperative agonist binding and may be used for future drug discovery efforts at these important receptors.

Appendix

Cooperative agonist operational model

A model of signal transduction by a receptor with nB binding sites is displayed in the equilibrium:

Where K_E is the value of $A_{nB}R$ that elicits half the maximal system effect and agonist affinity for each site can be described by the equilibrium dissociation constants:

$$K_{A1} = \frac{[A][R]}{[AR]}, K_{A2} = \frac{[A][AR]}{[A_2R]}, K_{A3} = \frac{[A][A_2R]}{[A_3R]}, \text{ etc}$$

We see that $K_{A1} \times K_{A2} \times K_{A3} \times \dots \times K_{A_{nB}} = \frac{[A]^{nB}[R]}{[A_{nB}R]} = K_A^{nB}$, where K_A is the geometric mean of the individual equilibrium dissociation constants.

For simplicity, the receptor is considered either empty (R) or fully occupied ($A_{nB}R$): $(nB)A + R \xrightleftharpoons{K_A^{nB}} A_{nB}R \xrightarrow{K_E} E$

$$K_A^{nB} = \frac{[A]^{nB}[R]}{[A_{nB}R]}$$

The total receptor concentration can be expressed as:

$$[R_0] = [R] + [A_{nB}R]$$

where

$$[R] = \frac{K_A^{nB}[A_{nB}R]}{[A]^{nB}}$$

therefore

$$[R_0] = \frac{K_A^{nB}[A_{nB}R]}{[A]^{nB}} + [A_{nB}R]$$

$$[R_0] = [A_{nB}R] \left(\frac{K_A^{nB}}{[A]^{nB}} + 1 \right)$$

$$[R_0] = [A_{nB}R] \left(\frac{K_A^{nB} + [A]^{nB}}{[A]^{nB}} \right)$$

Receptor occupancy is thus denoted:

$$[A_{nB}R] = \frac{[R_0][A]^{nB}}{K_A^{nB} + [A]^{nB}}$$

In accordance with the scheme of the operational model of agonism, the logistic function for the transduction of occupancy into response is: $E = \frac{E_m [A_{nB}R]^{nT}}{K_E^{nT} + [A_{nB}R]^{nT}}$ where nT is a logistic slope factor describing the transduction of agonist binding into a response (the transducer slope).

Using the previous expression of $[A_{nB}R]$ gives:

$$E = \frac{E_m \left(\frac{[R_0][A]^{nB}}{K_A^{nB} + [A]^{nB}} \right)^{nT}}{K_E^{nT} + \left(\frac{[R_0][A]^{nB}}{K_A^{nB} + [A]^{nB}} \right)^{nT}}$$

Multiplying numerator and denominator by $(K_A^{nB} + [A]^{nB})^{nT}$ gives:

$$E = \frac{E_m [R_0]^{nT} [A]^{nBnT}}{K_E^{nT} (K_A^{nB} + [A]^{nB})^{nT} + [R_0]^{nT} [A]^{nBnT}}$$

Dividing through by K_E and redefining $\frac{[R_0]}{K_E}$ as τ_A gives an operational model of agonism for a receptor with nB binding sites (Eq 2 in the main text):

$$E = \frac{E_m \tau_A^{nT} [A]^{nBnT}}{(K_A^{nB} + [A]^{nB})^{nT} + \tau_A^{nT} [A]^{nBnT}}$$

For use in Graphpad Prism or similar software, the above equation is described by the following notations, where n_T or n_B will likely need to be fixed to a known or theoretical value to fit real experimental data to this equation, and where a "Basal" response parameter is introduced to accommodate ligand-independent effects that deviate from zero:

$$KA = 10^{\wedge} \text{LogKA}$$

$$A = 10^{\wedge} X$$

$$\text{tau} = 10^{\wedge} \text{Logtau}$$

$$\text{Part1} = (E_m - \text{Basal}) * \text{tau} * (A^{\wedge} nB)$$

$$\text{Part2} = \text{tau} * (A^{\wedge} nB) + (A^{\wedge} nB) + (KA^{\wedge} nB)$$

$$Y = \text{Basal} + (\text{Part1}^{\wedge} nT) / (\text{Part2}^{\wedge} nT)$$

Operational model of allosterism with cooperative agonist binding

In a ternary complex consisting of a receptor (lacking constitutive activity), an orthosteric agonist that binds nB binding sites, and an allosteric modulator, the stimulus-generating species are $A_{nB}R$, BR and $A_{nB}RB$. A model of ligand-receptor interactions in this ternary complex is displayed in the equilibrium:

Where $K_A^{nB} = \frac{[A]^{nB}[R]}{[A_{nB}R]}$, $K_B = \frac{[B][R]}{[BR]}$, and $\frac{K_B}{\alpha} = \frac{[A_{nB}R][B]}{[A_{nB}RB]}$

From the latter expression we obtain:

$$\alpha = \frac{K_B[A_{nB}RB]}{[A_{nB}R][B]}$$

Assuming the pharmacological effect (E) is a function of the total stimulus (S_T) arising from the sum of the stimuli generated from each individual ligand-bound receptor species, then:

$$S_T = S_{A_{nB}R} + S_{BR} + S_{A_{nB}RB}$$

It is further assumed that the stimulus (S) generated from each individual ligand-bound receptor species is proportional to the product of the intrinsic efficacy of the ligand (ε) and the concentration of the ligand-bound receptor species, thus:

$$S_{A_{nB}R} = \varepsilon_{A_{nB}}[A_{nB}R]; S_{BR} = \varepsilon_B[BR]; S_{A_{nB}RB} = \varepsilon_{A_{nB}B}[A_{nB}RB]; \text{ and } \varepsilon_{A_{nB}B} = \beta\varepsilon_{A_{nB}}$$

where $\varepsilon_{A_{nB}}$ denotes the intrinsic efficacy of the orthosteric agonist, ε_B denotes the intrinsic efficacy of the allosteric modulator, and β is a coupling factor that describes the effect of the allosteric modulator on the intrinsic efficacy of the orthosteric agonist when the two ligands are bound to the same receptor.

Thus, the effect (E) of an agonist in the presence of an allosteric modulator is processed through the following logistic equation

$$E = \frac{E_m S_T^{nT}}{K_S^{nT} + S_T^{nT}}$$

where E_m denotes the maximum possible response, K_S denotes a constant that governs the efficiency of stimulus-response coupling and nT denotes a logistic slope factor (the transducer slope).

If we consider the total receptor concentration:

$$[R_0] = [R] + [A_{nB}R] + [BR] + [A_{nB}RB]$$

where

$$[A_{nB}R] = \frac{[R_0][A]^{nB}}{[A]^{nB} \left(1 + \frac{\alpha[B]}{K_B}\right) + K_A^{nB} \left(1 + \frac{[B]}{K_B}\right)}$$

$$[BR] = \frac{[R_0][B]}{[B] \left(1 + \frac{\alpha[A]^{nB}}{K_A^{nB}}\right) + K_B \left(1 + \frac{[A]^{nB}}{K_A^{nB}}\right)} \text{ and}$$

$$[A_{nB}RB] = \frac{[R_0][A]^{nB}}{[A]^{nB} \left(1 + \frac{K_B}{\alpha[B]}\right) + K_A^{nB} \left(\frac{1}{\alpha} + \frac{K_B}{\alpha[B]}\right)};$$

substituting the above terms into $E = \frac{E_m S_T^{nT}}{K_S^{nT} + S_T^{nT}}$ gives the following operational model of allosterism at a receptor with nB orthosteric agonist binding sites (Eq 4 in the main text):

where

$$\tau_A = \frac{\varepsilon_{A_{nB}}[R_0]}{K_S}$$

and

$$\tau_B = \frac{\varepsilon_B[R_0]}{K_S}$$

For use in Graphpad Prism or similar software, the above equation is described by the following notations, where nT or nB will likely need to be fixed to a known or theoretical value to fit real experimental data to this equation:

$$\begin{aligned} KA &= 10^{\wedge} \text{LogKA} \\ KB &= 10^{\wedge} \text{LogKB} \\ \text{tauA} &= 10^{\wedge} \text{LogtauA} \\ \text{tauB} &= 10^{\wedge} \text{LogtauB} \\ A &= (10^{\wedge} X) \\ \alpha &= 10^{\wedge} \text{Logalpha} \\ \beta &= 10^{\wedge} \text{Logbeta} \\ B &= 10^{\wedge} \text{LogAllo} \end{aligned}$$

$$\text{Part1} = \text{tauA} * (A^{\wedge} nB) * (KB + \alpha * \beta * B) + \text{tauB} * B * (KA^{\wedge} nB)$$

$$\text{Part2} = (A^{\wedge} nB) * KB + (KA^{\wedge} nB) * KB + B * (KA^{\wedge} nB) + \alpha * (A^{\wedge} nB) * B$$

$$\text{Stim} = \text{Part1} / \text{Part2}$$

$$Y = \text{Basal} + ((Em - \text{Basal}) * (\text{Stim}^{\wedge} nT)) / ((\text{Stim}^{\wedge} nT) + (1^{\wedge} nT))$$

For the purposes of the current study, the model has been simplified further to enable analysis of data when the orthosteric agonist is a full agonist. Therefore, equation 4 in the manuscript reduces to:

$$E = \frac{E_m \left(\tau_A [A]^{nB} (K_B + \alpha \beta [B]) + \tau_B [B] K_A^{nB} \right)^{nT}}{K_A^{nB nT} (K_B + [B])^{nT} + \left(\tau_A [A]^{nB} (K_B + \alpha \beta [B]) + \tau_B [B] K_A^{nB} \right)^{nT}}$$

Dividing through by τ_A^{nT} , and defining $[EC_{50}] = K_A / \tau_A$ yields the following expression:

$$E = \frac{E_m \left([A]^{nB} (K_B + \alpha \beta [B]) + \tau_B [B] [EC_{50}]^{nB} \right)^{nT}}{[EC_{50}]^{nB nT} (K_B + [B])^{nT} + \left([A]^{nB} (K_B + \alpha \beta [B]) + \tau_B [B] [EC_{50}]^{nB} \right)^{nT}}$$

Authorship Contributions

Participated in research design: Gregory, Christopoulos, Leach.

Conducted experiments: Diao.

Contributed new reagents or analytic tools: Giraldo, Christopoulos.

Performed data analysis: Diao, Gregory, Giraldo, Leach.

$$E = \frac{E_m \left(\tau_A [A]^{nB} (K_B + \alpha \beta [B]) + \tau_B [B] [K_A]^{nB} \right)^{nT}}{\left([A]^{nB} K_B + K_A^{nB} K_B + K_A^{nB} [B] + \alpha [A]^{nB} [B] \right)^{nT} + \left(\tau_A [A]^{nB} (K_B + \alpha \beta [B]) + \tau_B [B] K_A^{nB} \right)^{nT}}$$

Wrote or contributed to the writing of the manuscript: Gregory, Giraldo, Christopoulos, Leach.

References

- Abdul-Ridha A, Lane JR, Mistry SN, López L, Sexton PM, Scammells PJ, Christopoulos A, and Canals M (2014) Mechanistic insights into allosteric structure-function relationships at the M₁ muscarinic acetylcholine receptor. *J Biol Chem* **289**:33701–33711.
- Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, and Scammells PJ (2009) Allosteric modulators of the adenosine A₁ receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. *J Med Chem* **52**:4543–4547.
- Black JW and Leff P (1983) Operational models of pharmacological agonism. *Proc R Soc Lond B Biol Sci* **220**:141–162.
- Black JW, Leff P, Shankley NP, and Wood J (1985) An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. *Br J Pharmacol* **84**:561–571.
- Brea J, Castro M, Giraldo J, López-Giménez JF, Padín JF, Quintián F, Cadavid MI, Vilaró MT, Mengod G, Berg KA, et al. (2009) Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine_{2A} receptor homodimers. *Mol Pharmacol* **75**:1380–1391.
- Brown EM (1983) Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. *J Clin Endocrinol Metab* **56**:572–581.
- Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. *Trends Pharmacol Sci* **19**:351–357.
- Cook AE, Mistry SN, Gregory KJ, Furness SG, Sexton PM, Scammells PJ, Conigrave AD, Christopoulos A, and Leach K (2015) Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics. *Br J Pharmacol* **172**:185–200.
- Davey AE, Leach K, Valant C, Conigrave AD, Sexton PM, and Christopoulos A (2012) Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. *Endocrinology* **153**:1232–1241.
- Diepenhorst NA, Leach K, Keller AN, Rueda P, Cook AE, Pierce TL, Nowell C, Pastoureau P, Sabatini M, Summers RJ, et al. (2018) Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity. *Br J Pharmacol* **175**:4095–4108.
- Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. *Mol Pharmacol* **33**:187–194.
- Geng Y, Mosyak L, Kurinov I, Zuo H, Sturchler E, Cheng TC, Subramanyam P, Brown AP, Brennan SC, Mun HC, et al. (2016) Structural mechanism of ligand activation in human calcium-sensing receptor. *eLife* **5**:e13662.
- Giraldo J (2015) Operational models of allosteric modulation: caution is needed. *Trends Pharmacol Sci* **36**:1–2.
- Huang Y, Zhou Y, Castiblanco A, Yang W, Brown EM, and Yang JJ (2009) Multiple Ca²⁺ binding sites in the extracellular domain of the Ca²⁺-sensing receptor corresponding to cooperative Ca²⁺ response. *Biochemistry* **48**:388–398.
- Keller AN, Kufareva I, Josephs TM, Diao J, Mai VT, Conigrave AD, Christopoulos A, Gregory KJ, and Leach K (2018) Identification of global and ligand-specific calcium sensing receptor activation mechanisms. *Mol Pharmacol* **93**:619–630.
- Kenakin TP (2012) Biased signalling and allosteric machines: new vistas and challenges for drug discovery. *Br J Pharmacol* **165**:1659–1669.
- Leach K, Conigrave AD, Sexton PM, and Christopoulos A (2015) Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias. *Trends Pharmacol Sci* **36**:215–225.
- Leach K, Davey AE, Felder CC, Sexton PM, and Christopoulos A (2011) The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M₄ muscarinic acetylcholine receptor. *Mol Pharmacol* **79**:855–865.
- Leach K, Gregory KJ, Kufareva I, Khajehali E, Cook AE, Abagyan R, Conigrave AD, Sexton PM, and Christopoulos A (2016) Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. *Cell Res* **26**:574–592.
- Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, Sexton PM, and Christopoulos A (2010) Molecular mechanisms of action and in vivo validation of an M₄ muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. *Neuropsychopharmacology* **35**:855–869.
- Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. *Trends Pharmacol Sci* **28**:382–389.
- May LT, Bridge LJ, Stoddart LA, Briddon SJ, and Hill SJ (2011) Allosteric interactions across native adenosine-A₃ receptor homodimers: quantification using single-cell ligand-binding kinetics. *FASEB J* **25**:3465–3476.
- Moreno Delgado D, Möller TC, Ster J, Giraldo J, Maurel D, Rovira X, Scholler P, Zwier JM, Perroy J, Durroux T, et al. (2017) Pharmacological evidence for a metabotropic glutamate receptor heterodimer in neuronal cells. *eLife* **6**:e25233.
- Mutel V, Ellis GJ, Adam G, Chaboz S, Nilly A, Messer J, Bleuel Z, Metzler V, Malherbe P, Schlaefer EJ, et al. (2000) Characterization of [³H]quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. *J Neurochem* **75**:2590–2601.
- Sato S, Huang XP, Kroeze WK, and Roth BL (2016) Discovery and characterization of novel GPR39 agonists allosterically modulated by zinc. *Mol Pharmacol* **90**:726–737.
- Sengmany K and Gregory KJ (2016) Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias. *Br J Pharmacol* **173**:3001–3017.
- Sengmany K, Hellyer SD, Albold S, Wang T, Conn PJ, May LT, Christopoulos A, Leach K, and Gregory KJ (2019) Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology. *Neuropharmacology* **149**:83–96.
- Sengmany K, Singh J, Stewart GD, Conn PJ, Christopoulos A, and Gregory KJ (2017) Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: implications for optimizing preclinical neuroscience drug discovery. *Neuropharmacology* **115**:60–72.
- Sinkins WG and Wells JW (1993) G protein-linked receptors labeled by [³H]histamine in guinea pig cerebral cortex. II. Mechanistic basis for multiple states of affinity [corrected] [published correction appears in *Mol Pharmacol* (1993) **44**:1278]. *Mol Pharmacol* **43**:583–594.
- Stockton JM, Birdsall NJ, Burgen AS, and Hulme EC (1983) Modification of the binding properties of muscarinic receptors by gallamine. *Mol Pharmacol* **23**:551–557.
- Storjohann L, Holst B, and Schwartz TW (2008) Molecular mechanism of Zn²⁺ agonism in the extracellular domain of GPR39. *FEBS Lett* **582**:2583–2588.
- Vivo M, Lin H, and Strange PG (2006) Investigation of cooperativity in the binding of ligands to the D₂ dopamine receptor. *Mol Pharmacol* **69**:226–235.
- Zhang C, Zhuo Y, Moniz HA, Wang S, Moremen KW, Prestegard JH, Brown EM, and Yang JJ (2014) Direct determination of multiple ligand interactions with the extracellular domain of the calcium-sensing receptor. *J Biol Chem* **289**:33529–33542.

Address correspondence to: Katie Leach, Drug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, Melbourne, VIC 3052, Australia. E-mail: katie.leach@monash.edu